Inventiva S.A.
HealthcareNASDAQ:IVA · NASDAQ Global Market
+$0.05 today
Vol 1.01M · Avg 0.42M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1171.5%
avg 117.2%
ROIC
-64.4%
avg -289.0%
ROA
-136.7%
avg -64.5%
Analysis
ROE is currently the strongest return metric at 1171.5% versus its period average of 117.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pierre Broqua | Co-Founder | $475,000.00 | — | 64 | — | — |
Jean Volatier | Executive VP Finance & Corporate Social Responsibility | $410,135.00 | — | 61 | — | — |
Jason A. Campagna | President of Research & Development and Chief Medical Officer | $390,077.00 | — | 60 | — | — |
Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | $260,788.00 | — | 57 | — | — |
Andrew Obenshain | Chief Executive Officer | $175,609.00 | — | 52 | — | — |
Nazira Amra | Chief Commercial Strategy Officer | — | — | — | — | — |
Pascaline Clerc | Executive Vice President of External and Corporate Affairs | — | — | 46 | — | — |
Susan Coles | Chief Legal Officer | — | — | 60 | — | — |
Axel-Sven Malkomes | Chief Financial Officer | — | — | 59 | — | — |
Eric Duranson | General Counsel | — | — | 52 | — | — |
Nathalie Harroy | Head of Human Resources | — | — | 59 | — | — |
Pamela Herbster | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +25.7% | +40.9% (13yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +25.7% over three years. Forward estimates point to Revenue at +40.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Who manages IVA?
Inventiva S.A. (IVA) lists 12 active executives. The top listed executive is Andrew Obenshain, Chief Executive Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.